Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has issued an update.
Proteomics International Laboratories Ltd has bolstered its cash reserves with a $2.2 million R&D tax incentive for the 2024-25 financial year. This funding supports the commercialization of their diagnostic tests, including Promarker®D for Diabetic Kidney Disease and Promarker®Endo for Endometriosis, as well as their ongoing R&D efforts. The rebate, part of the Australian Government’s initiative to encourage beneficial research, highlights the company’s commitment to advancing its diagnostic pipeline and strengthening its market position.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia, is a medical technology company specializing in precision diagnostics and bio-analytical services. The company focuses on proteomics, the large-scale study of proteins, aiming to enhance disease treatment through innovative diagnostic tools.
Average Trading Volume: 338,280
Technical Sentiment Signal: Sell
Current Market Cap: A$58.11M
See more data about PIQ stock on TipRanks’ Stock Analysis page.